The 48th Annual ICAAC/IDSA 46th Annual Meeting

BROWSE COVERAGE

ICAAC/IDSA 2008 Newsroom

HIV Treatment News From the 48th ICAAC (January/February 2009)
A round-up of reports.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Starting Therapy Earlier Found to Improve Survival (January/February 2009)
Study raises the implications of more testing, less transmission.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Efavirenz Significantly Reduces Levels of Some Oral Contraceptives (November/December 2008)
In HIV Treatment Bulletin, from HIV i-Base
Study Shows People Can Safely Switch to Atripla (December 2008)
To read PDF, click here
From Project Inform
Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here
In Project Inform Perspective, from Project Inform
Peculiar Type of KS Emerges in Healthier Individuals (November 7, 2008)
From Project Inform
Some AIDS-Defining Conditions Now Diagnosed at Higher CD4s (November 6, 2008)
From Project Inform
New AIDS Drug, New Abbott Rival (October 30, 2008)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
CD4+ Cell Count Decline in HIV-Positive Patients Is Growing More Rapid, Military Study Suggests (October 28, 2008)
A 20-year analysis of 2,000 U.S. military patient records appears to add credence to the argument that HIV has grown more virulent than it was during the early years of the epidemic. (An interview with Nancy Crum-Cianflone, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Merck's Antiretroviral Isentress More Efficient in Suppressing HIV Among Untreated Patients (October 28, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Smallpox Vaccine Safe in HIV-Infected Patients (October 28, 2008)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Superinfection More Common Than Expected Among Heterosexual Cohabiting Couples in Zambia, Small Study Finds (October 28, 2008)
Genetic screening of HIV strains reveals cases of HIV superinfection among two of 15 couples in a Zambian cohort. (An interview with Colleen Kraft, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Analysis of CASTLE Finds No Benefit for Once-Daily Dosing (October 27, 2008)
From Project Inform
Antiretroviral Treatment Should Start Earlier, Study Says (October 27, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
CASTLE Study Compares Reyataz to Kaletra (October 27, 2008)
From Project Inform
Conference Highlights: New Studies on New (and Not Quite as New) HIV Meds (October 27, 2008)
From Lexiva to Reyataz and from Prezista to Isentress, several clinical trials were presented at ICAAC/IDSA 2008 that showed promising results for our more recently approved HIV medications. Eric Daar, M.D., gives us the lowdown on these studies and how they may change the HIV treatment landscape.
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body
Conference Highlights: Which Studies Are Most Likely to Change the Lives of People With HIV? (October 27, 2008)
Joel Gallant, M.D., one of the United States' foremost HIV experts, walks us through some of the most important findings presented at ICAAC/IDSA 2008.
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body
Diabetes Risk Appears Lower for HIV-Positive Patients Than Negative Patients (October 27, 2008)
A large, ongoing study of U.S. military veterans also suggests that the usual risk factors for diabetes, not HIV itself, are the main drivers of diabetes in HIV-positive people. (An interview with Adeel A. Butt, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Does Kaletra Monotherapy Work? Depends on Who You Ask (October 27, 2008)
Project Inform says the latest findings on Kaletra monotherapy are anything but positive.
From Project Inform
Four Posters Add to Our Knowledge of Lexiva (October 27, 2008)
From Project Inform
HAART Use Improves Hepatitis B Vaccine Response, Even at High CD4 Counts (October 27, 2008)
HIV-positive patients are approximately twice as likely to respond to hepatitis B vaccination if they are receiving antiretroviral therapy, regardless of their CD4+ cell count at the time of vaccination, according to a study by researchers with the U.S. military. (An interview with Michael Landrum, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
HIV Treatment Tied to Decreased Bone Mineral Density, Study Finds (October 27, 2008)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Hospitalization Risk Similar Between HAART Responders and Nonresponders for 90 Days After Starting Therapy (October 27, 2008)
The benefits of HAART initiation -- at least in terms of preventing or ameliorating illnesses that require hospitalization -- may not manifest themselves for up to three months, according to a sizeable study by Johns Hopkins University researchers. Women were more likely to be hospitalized than men, and choice of HAART regimen appeared to have no impact. (An interview with Stephen Berry, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Impact of Testosterone Levels on Bone Mineral Density May Be More Pronounced in HIV-Infected Patients (October 27, 2008)
A retrospective, controlled study of 237 patients finds that, among patients with low testosterone levels, those who are HIV infected have lower bone mineral density than those who are HIV uninfected. (An interview with Ranjani Raghunathan, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Long-Term Safety Study of Vicriviroc Presented (October 27, 2008)
From Project Inform
Patients on Tenofovir/Emtricitabine May Face Higher Bone Risk From Vitamin D Insufficiency (October 27, 2008)
A small study finds that, although vitamin D insufficiency is quite common among HIV-positive people, it may be a particular risk for patients receiving tenofovir/emtricitabine: These patients appear especially likely to have elevated parathyroid hormone levels, which has been associated with bone problems. (An interview with Kate Childs, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Studies: Newer HIV Drugs More Tolerable for Many (October 27, 2008)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Two Studies Look at Intelence (October 27, 2008)
From Project Inform
96-Week ARTEMIS Data Indicate Darunavir Is Superior to Lopinavir in Naive Patients (October 26, 2008)
Following 48-week data that proved darunavir's non-inferiority to lopinavir, these new, even more encouraging 96-week data appear likely to solidify the drug's role in first-line therapy. (An interview with Tony Mills, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Crafting First-Line Regimens: So Easy a General Practitioner Could Do It? (October 26, 2008)
We may have more antiretrovirals to choose from than ever before, but selecting an initial HAART regimen today is often a choice between just two regimens, a new study indicates. The findings suggest it may be realistic for primary care physicians and general practitioners to shoulder more of the HIV care burden. (An interview with James McKinnell, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
HEAT: Virologic Failure Rates Similar (and Low), Emerging Resistance Uncommon on Abacavir/Lamivudine vs. Tenofovir/Emtricitabine (October 26, 2008)
The similarities between these two first-line nucleoside backbones is reiterated in a new examination of virologic failure data from the 96-week results of the HEAT study. (An interview with Benjamin Young, M.D., Ph.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Large Study Supports Earlier Treatment (October 26, 2008)
From Project Inform
RDEA Study Supports Further Development of New NNRTI (October 26, 2008)
From Project Inform
Results From Elvucitabine Study Unimpressive (October 26, 2008)
From Project Inform
Starting HAART: Should 500 Become the New 350? (October 26, 2008)
Mari Kitahata, M.D., and Daniel Kuritzkes, M.D., discuss a 5,926-patient trial that found a 74% higher mortality risk among those who deferred HAART until their CD4 dropped below 350 rather than initiating when their CD4 was between 351 and 500. Dr. Kuritzkes also touches on new developments in HIV drug resistance.
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Study Explains Why Isentress Works Well and Resists Resistance (October 26, 2008)
From Project Inform
Study May Point Way Forward for Bevirimat (October 26, 2008)
From Project Inform
Study Shows Better Results From Vicriviroc When New Trofile Test Is Used (October 26, 2008)
From Project Inform
Study Supports Use of Isentress for First-Line Treatment (October 26, 2008)
From Project Inform
Switch to Tenofovir/Emtricitabine From Abacavir/Lamivudine Appears to Halt Lipoatrophy: Gilead 934 Rollover (October 26, 2008)
In a prospective rollover study from the landmark Gilead 934 trial, patients who switched NRTI combinations ceased losing fat, maintained virologic suppression and exhibited no significant change in creatinine clearance or glomerular filtration rate. (An interview with Edwin DeJesus, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Switching From Combivir to Truvada Keeps HIV Undetectable, Improves Blood Fats, But Fails to Improve Limb Fat (October 26, 2008)
From Project Inform
Trend Toward Fewer AIDS-Defining Conditions Among Patients Receiving Raltegravir vs. Placebo (October 26, 2008)
A new examination of 48-week BENCHMRK data found a nearly twofold reduction in AIDS-defining events among patients on raltegravir, but the findings failed to reach statistical significance. Intriguingly, greater resistance did not appear to be a predictor of AIDS-defining events. (An interview with Joseph Eron Jr., M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Adding GM-CSF to Hepatitis B Vaccine Fails to Work (October 25, 2008)
From Project Inform
African Americans With HIV Have Higher OI Rates and Hospital Mortality, but Lower HCV Rates, Than Whites, Hospital Survey Finds (October 25, 2008)
A massive, nationwide hospital survey reveals that black, hospitalized HIV-infected patients experience greater morbidity and mortality than their white counterparts -- but also appear less likely to be coinfected with hepatitis C. (An interview with Christine Oramasionwu, Pharm.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
CD4-Based ADAP Waiting Lists Can Save More Lives Than First-Come, First-Served Lists, Study Suggests (October 25, 2008)
ADAP waiting lists that determine enrollment priority based on a patient's CD4 count can ensure lower mortality rates than ADAP waiting lists that determine priority on a first-come, first-served basis, according to calculations by a team of Massachusetts researchers. (An interview with Benjamin Linas, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Ensuring ADAPs Realize the Best Health Outcomes for All Eligibles (October 25, 2008)
From Project Inform
Ethnicity Does Matter When It Comes to Quality of HIV Care in United States, Survey Finds (October 25, 2008)
African-American and Hispanic-American female patients often feel that their culture or ethnicity impacts their HIV care -- so much so, in fact, that many end up switching HIV care providers because of communication problems, according to a nationwide survey. (An interview with Sally Hodder, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Four Weeks of Therapy Enough to Prevent MTC Transmissions (October 25, 2008)
From Project Inform
HIV-Positive U.S. Women More Likely to Abort Pregnancy Than HIV-Negative Women (October 25, 2008)
Abortions were more common among pregnant, HIV-infected women receiving care at a major Mid-Atlantic clinic, despite findings that there was no greater risk of stillbirth and a lower risk of miscarriage. (An interview with Susan Matcha, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Many Black, HIV-Positive Women in Mississippi Are Lost to Care After Giving Birth (October 25, 2008)
The U.S. health care system has succeeded wonderfully at preventing mother-to-child HIV transmission. But is it failing to provide low-income, HIV-infected women with the care they need after they have given birth? (An interview with Aadia Rana, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
Meningococcal Vaccine Appears Safe in Youth With HIV (October 25, 2008)
From Project Inform
The Hidden Costs of Prior Authorization: Wasted Time and Medication Delays (October 25, 2008)
Insurers may save money by requiring prior authorization for medication access, but when it comes to HIV care, health care providers (and, as a result, their patients) are the ones who suffer, according to real-world observations of an Alabama HIV Clinic. (An interview with James Willig, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.